Harmony Biosciences (HRMY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Positioning and Financial Outlook

• Entering 2025 in a strong position with a catalyst-rich, late-stage pipeline and a profitable, self-funding business model.

• Preliminary 2024 net revenue reached $714 million, with 2025 guidance of $820–$860 million and a ~45% CAGR in net revenue from 2020 to 2024.

• WAKIX is on track to become a billion-dollar-plus opportunity in narcolepsy, supported by a broad prescriber base and unique non-scheduled status.

• The pipeline is expected to deliver over $3 billion in future revenue, with multiple franchises each targeting $1–$2 billion peak sales.

• Over $500 million in cash and continued profitability enable further pipeline expansion and business development.

Pipeline and Clinical Development Highlights

• Up to six clinical programs will be in phase III by year-end 2025, spanning eight assets and 13 development programs.

• Key 2025 catalysts include: Q1—FDA decision on pitolisant for idiopathic hypersomnia; Q2—preclinical data on orexin 2 agonist; Q3—phase III data for ZYN002 in Fragile X syndrome; Q4—initiation of pivotal trial for next-gen pitolisant HD.

• ZYN002, a synthetic cannabidiol gel, targets Fragile X syndrome and 22q deletion syndrome, with potential to be the first approved treatment for Fragile X.

• Next-gen pitolisant programs aim to address unmet needs in narcolepsy, idiopathic hypersomnia, and myotonic dystrophy, with patent protection into the 2040s.

• EPX-100, a repurposed antihistamine and differentiated 5HT2 agonist, is in phase III for Dravet and Lennox-Gastaut syndromes, with top-line data expected in 2026.

Commercial and Market Dynamics

• WAKIX benefits from access to the full prescriber and patient base, unlike REMS-restricted competitors, and is one of the most successful orphan/rare disease launches.

• Growth is driven by its non-scheduled status, broadening reach beyond REMS-enrolled professionals.

• The commercial model leverages a single patient hub and closed specialty pharmacy distribution for efficient launches.

• Over 50% of narcolepsy patients in the U.S. remain undiagnosed, indicating significant market expansion potential.

• Pitolisant franchise expansion (GR and HD formulations) expected to add $1B+ and $300–$500M opportunities, respectively.